Zobrazeno 1 - 10
of 176
pro vyhledávání: '"Jatin Shah"'
Autor:
Sangmin Lee, Sanjay Mohan, Jessica Knupp, Kamal Chamoun, Adrienne de Jonge, Fan Yang, Erkan Baloglu, Jatin Shah, Michael G. Kauffman, Sharon Shacham, Bhavana Bhatnagar
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-4 (2022)
Abstract Patients with higher-risk myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs) have limited therapeutic options and an expected overall survival (OS) of 3–5 months. Eltanexor is an investigational oral selective inhi
Externí odkaz:
https://doaj.org/article/45d616db3d9d47b9b350d3ed3b69c2ff
Autor:
Padma Rekha Jirge, Madhuri Milind Patil, Rohit Gutgutia, Jatin Shah, Mridubhashini Govindarajan, Varsh Samson Roy, Nalini Kaul-Mahajan, Faddy I Sharara
Publikováno v:
Journal of Human Reproductive Sciences, Vol 15, Iss 2, Pp 112-125 (2022)
Controlled ovarian stimulation has been an integral part of in vitro fertilisation (IVF) treatment cycles. Availability of different gonadotropins for ovarian stimulation and gonadotropin releasing hormone (GnRH) analogues for prevention of premature
Externí odkaz:
https://doaj.org/article/f92d4ffdf7b34294a40ddc80ac308559
Autor:
Kyaw Z. Thein, Sarina A. Piha-Paul, Apostolia Tsimberidou, Daniel D. Karp, Filip Janku, Siqing Fu, Vivek Subbiah, David S. Hong, Timothy A. Yap, Jatin Shah, Denái R. Milton, Lacey McQuinn, Jing Gong, Yanyan Tran, Brett W. Carter, Rivka Colen, Funda Meric-Bernstam, Aung Naing
Publikováno v:
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-6 (2021)
Abstract Selinexor, an oral selective inhibitor of nuclear export (SINE), was demonstrated to hinder the DNA damage repair (DDR) system by reducing DDR proteins while enhancing the killing of cancer cells by DDR-based therapeutics in vivo studies. In
Externí odkaz:
https://doaj.org/article/c459d13c2a2d4dd98828b2e651417c38
Autor:
Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay Nooka, Dan Vogl, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Paul Richardson, Noa Biran, David Siegel, Philip Vlummens, Chantal Doyen, Thierry Facon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy, Luciano Costa, James E. Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc Raab, David Dingli, Sascha Tuchman, Frenzel Laurent, Ravi Vij, Gary Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri Parker, Robert Frank Cornell, Karlin Lionel, Sylvain Choquet, Jagannath Sundar
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma
Externí odkaz:
https://doaj.org/article/ad0d07b841e64c82afc2fcdee19751cf
Autor:
Joseph Lopez, MD, MBA, Nancy Qin, BA, Robbie Woods, MD, Marjorie Golden, MFA, CDT, Harrison Spatz, DMD, MS, Jatin Shah, MD, Leonard H. Wexler, MD, Joseph Randazzo, DDS, Suzanne L. Wolden, MD, David H. Abramson, MD
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 10, Iss 10, p e4581 (2022)
SUMMARY. A 20-month-old boy presented with biopsy-proven recurrent alveolar rhabdomyosarcoma without metastasis. He was previously treated with multiagent chemotherapy and external beam irradiation showing a complete response. Upon relapse, he was tr
Externí odkaz:
https://doaj.org/article/cde7d09b3e494fec931a9f0a6b8f8ba8
Autor:
Marie Maerevoet, Josee M. Zijlstra, George Follows, Rene-Olivier Casasnovas, J. S. P. Vermaat, Nagesh Kalakonda, Andre Goy, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger, Paolo Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan-Manuel Sancho, Michael Schuster, Miklos Egyed, Fritz Offner, Theodoros P. Vassilakopoulos, Priyanka Samal, Matthew Ku, Xiwen Ma, Kelly Corona, Kamal Chamoun, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Miguel Canales
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Abstract Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of
Externí odkaz:
https://doaj.org/article/a32f7416ac1d4ff49db82a15d0e6860f
Autor:
Kyaw Z. Thein, Siqing Fu, Filip Janku, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Daniel D. Karp, Jatin Shah, Denái R. Milton, Jing Gong, Selma Sulovic, Lacey McQuinn, Bettzy A. Stephen, Rivka R. Colen, Brett W. Carter, Funda Meric-Bernstam, Aung Naing
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 10-12 (2022)
Externí odkaz:
https://doaj.org/article/dbd595d620e44cfc834f3c0087d00433
Autor:
Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špička, Ludĕk Pour, Iryna Kriachok, Halyna Pylypenko, Vadim Doronin, Ganna Usenko, Reuben Benjamin, Tuphan K. Dolai, Dinesh K. Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Z. Badros, Larry D. Anderson, Nizar J. Bahlis, Michele Cavo, Yi Chai, Jacqueline Jeha, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Paul G. Richardson, Sebastian Grosicki
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Abstract Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in t
Externí odkaz:
https://doaj.org/article/20b9da9076424d1f8dc1d21eef7bc3c4
Autor:
Cristina Gasparetto, Suzanne Lentzsch, Gary Schiller, Natalie Callander, Sascha Tuchman, Christine Chen, Darrell White, Rami Kotb, Heather Sutherland, Michael Sebag, Muhamed Baljevic, William Bensinger, Richard LeBlanc, Chris Venner, Nizar Bahlis, Adriana Rossi, Noa Biran, Heidi Sheehan, Jean‐Richard Saint‐Martin, Dane Van Domelen, Kazuharu Kai, Jatin Shah, Sharon Shacham, Michael Kauffman, Brea Lipe
Publikováno v:
eJHaem, Vol 2, Iss 1, Pp 56-65 (2021)
Abstract We assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export (100 mg once weekly [QW] or 60 mg twice weekly), in combination
Externí odkaz:
https://doaj.org/article/69e08a3b96d24bf1a3690cc152ca6a6b
Autor:
Paul G. Richardson, Sundar Jagannath, Ajai Chari, Dan T. Vogl, Meletios A. Dimopoulos, Philippe Moreau, David Dingli, Lee‐Jen Wei, Joshua Richter, Noa Biran, David Siegel, William Reichmann, Lingling Li, Shijie Tang, Jean‐Richard Saint‐Martin, Anita Joshi, Michael Kauffman, Jatin Shah, Sharon Shacham, Sagar Lonial
Publikováno v:
eJHaem, Vol 2, Iss 1, Pp 48-55 (2021)
Abstract Triple‐class‐refractory multiple myeloma (MM) describes MM refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. In the Phase IIb STORM study (NCT02336815), oral selinexor plus low‐dose de
Externí odkaz:
https://doaj.org/article/dc57c040186644f69a2171ddea55b3db